Rabbit anti-thymocyte globulin

DRUG12 trials

Sponsors

Astellas Pharma Inc, National Institute of Allergy and Infectious Diseases (NIAID), Sumitomo Pharma Switzerland GmbH, Stanford University, Columbia University

Conditions

Anemia, Sickle CellBlood and Marrow Transplant (BMT)Bone Marrow FailureComplete Atypical DiGeorge AnomalyComplete Atypical DiGeorge SyndromeComplete DiGeorge AnomalyComplete DiGeorge SyndromeDiGeorge Anomaly

Phase 1

Phase I/II Thymus Transplantation With Immunosuppression #950

CompletedNCT00579527

Sumitomo Pharma Switzerland GmbHComplete Atypical DiGeorge Anomaly, Complete Atypical DiGeorge Syndrome, Complete DiGeorge Anomaly +2

Start: 2005-12-19End: 2017-12-31Updated: 2022-03-25

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

CompletedNCT02472392

University of LouisvilleEWINGS SARCOMA

Start: 2013-04-30End: 2016-12-31Target: 10Updated: 2017-05-09

A Blood Stem Cell Transplant for Sickle Cell Disease

Active, not recruitingNCT03249831

City of Hope Medical CenterAnemia, Sickle Cell, Hemoglobinopathies, Sickle Cell Disease +2

Start: 2019-01-04End: 2027-01-25Updated: 2026-03-05

Phase 2

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

WithdrawnNCT00230035

National Institute of Allergy and Infectious Diseases (NIAID)Systemic Lupus Erythematosus

Start: 2005-09-30Updated: 2013-02-01

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

CompletedNCT00899847

Stanford UniversityBlood and Marrow Transplant (BMT), Multiple Myeloma, Transplantation, Autologous +1

Start: 2009-05-31End: 2014-12-31Updated: 2017-10-20

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

CompletedNCT01019876

Columbia UniversityBone Marrow Failure, Fanconi Anemia, Osteopetrosis +1

Start: 2002-09-30End: 2021-09-07Updated: 2024-10-31

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

CompletedNCT02757885

Emory UniversitySickle Cell Disease

Start: 2019-07-10End: 2021-12-14Updated: 2023-10-12

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

RecruitingNCT03980769

Fred Hutchinson Cancer CenterNon-Neoplastic Hematopoietic and Lymphoid Cell Disorder

Start: 2021-05-05End: 2028-07-01Target: 40Updated: 2026-03-12

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

RecruitingNCT07412470

SanofiKidney Transplant Rejection

Start: 2026-03-13End: 2033-08-15Target: 526Updated: 2026-03-27

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Not yet recruitingNCT07508787

Nefro Avillion Clinical Development, LLCRenal Transplant Failure and Rejection

Start: 2026-04-29End: 2028-03-28Target: 120Updated: 2026-04-02

Phase 4

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

CompletedNCT00113269

Astellas Pharma IncKidney Transplantation

Start: 2005-05-31End: 2009-03-31Updated: 2011-08-11

Unknown Phase

Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

Medical University of SilesiaGraves Orbitopathy

Start: 2020-01-01End: 2023-12-31Target: 20Updated: 2022-01-20

Related Papers

Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy—Preliminary Results From a Prospective Single-Center Study

Frontiers in Endocrinology2022-05-093 citations

Alemtuzumab induction in renal transplantation.

2011-05-01241 citations